RECRUITING

Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The primary objective of this study is to determine the ex-vivo prognostic accuracy of the Cybrid live tumor diagnostic platform using in-vivo RECIST 1.1 as the reference method.

Official Title

Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform (CYBRID-01)

Quick Facts

Study Start:2023-01-31
Study Completion:2026-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05478538

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

Catarina Costa
CONTACT
609-955-4927
ClinicalTrials@elephas.com

Principal Investigator

Fred Hausheer, MD, FACP
STUDY_DIRECTOR
Elephas

Study Locations (Sites)

UCLA Medical Center
Los Angeles, California, 90095
United States
James M Stockman Cancer Institute
Frederick, Maryland, 21702
United States
New York Cancer & Blood Specialists
Shirley, New York, 11967
United States
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27599
United States
Gabrail Cancer Center
Canton, Ohio, 44718
United States
JPS Health Network
Fort Worth, Texas, 76104
United States
Baylor Scott & White Research Institute
Temple, Texas, 76508
United States

Collaborators and Investigators

Sponsor: Elephas

  • Fred Hausheer, MD, FACP, STUDY_DIRECTOR, Elephas

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-01-31
Study Completion Date2026-12

Study Record Updates

Study Start Date2023-01-31
Study Completion Date2026-12

Terms related to this study

Keywords Provided by Researchers

  • Metastatic NSCLC
  • NSCLC
  • Non Small Cell Lung Cancer
  • Core needle biopsy
  • Live tumor fragments
  • Immunotherapy
  • Immunotherapy prediction
  • 3D culture
  • Ex vivo platform
  • Immune checkpoint inhibitors
  • Forceps biopsy

Additional Relevant MeSH Terms

  • Non Small Cell Lung Cancer
  • Metastatic Non Small Cell Lung Cancer
  • NSCLC
  • Metastatic NSCLC - Non-Small Cell Lung Cancer